DiSight Medical Secures Tens of Millions in Pre-A+ Funding to Accelerate Clinical Trials and R&D of Ophthalmic and Microsurgical Robots

VCBeat has learned at the earliest opportunity that,Recently, Hangzhou Dessight Biomedical Co. Ltd. (hereinafter referred to as “Dessight Biomedical”) announced the completion of its Pre-A+ financing round, raising tens of millions of yuan. The round was led by a cooperative fund of Infinity (Zhuhai) Venture Capital Management Co., Ltd. and Autek China Corporation, with participation from Shanghai New Silk Road Capital Holding Co., Ltd. and Beijing Fof Capital Co., Ltd. Existing shareholders, including Linear Capital, continued their support. Kaicheng Capital served as the exclusive financial advisor for this transaction.The funds raised in this round will primarily be used to accelerate the clinical trials of Dessight Biomedical’s ophthalmic surgical robot in humans, as well as to advance the R&D of its pipeline products, including microsurgical surgical robots. This marks Dessight Biomedical’s second financing round within six months, fully demonstrating strong recognition from the capital market.

Dessight Biomedical, established in July 2021, is a nationally recognized technology-based small and medium-sized enterprise. Its founding team hails from top-tier global robotics and artificial intelligence laboratories in Germany, as well as a Fortune 500 German pharmaceutical company. To date, Dessight Biomedical has filed for and been granted multiple invention patents in the United States and China, and has won several awards at prestigious global and domestic competitions.

The eye is the most delicate and complex organ in the human body.

Humans derive 90% of their information through vision, and the eye is the most delicate and complex organ in the human body. Among its structures, the fundus tissue is the most intricate, demanding the highest level of surgical precision, with an ideal accuracy of no more than 10 micrometers. However, the natural tremor of the human hand, approximately 100 micrometers, can easily cause retinal damage and impair visual recovery. Furthermore, there is a scarcity of senior ophthalmologists, the training cycle is exceptionally long, and performing delicate manual procedures under such conditions imposes significant stress.Dessight Biomedical leverages its technological advantages in personalized medical-engineering integration, multi-degree-of-freedom master-slave control, and proprietary flexible structures, positioning it as one of the first teams globally to achieve a motion precision of up to 3 micrometers in ophthalmic surgical robots.The product’s technology and R&D progress are both globally leading, with clinical trials imminent. Furthermore, the company’s microsurgical robot under development features nearly 20 ultra-high degrees of freedom, enabling it to assist microsurgeons in performing various highly difficult, ultra-microscopic, precise, and dexterous maneuvers—such as anastomosing lymphatic vessels, blood vessels, or nerves with diameters ranging from 0.3 to 0.8 millimeters. This system holds significant application value across multiple specialties, including otolaryngology, lymphatic surgery, neurosurgery, and plastic surgery.

Dr. Di Cui, CEO of Dessight Biomedicalstated: “We are delighted to announce the completion of our Pre-A+ financing round. This significant milestone will provide further support for accelerating the technological development of microsurgical robots and promoting their clinical application. We extend our gratitude to Infinity (Zhuhai) Venture Capital Management Co., Ltd. in collaboration with Autek China’s fund, Shanghai New Silk Road Capital Holding Co., Ltd., and Beijing Fof Capital Co., Ltd. for their support and recognition, as well as to our existing shareholders, including Linear Capital, for their continued backing. We also thank the Hangzhou Municipal Government and Shangcheng District Government for their ongoing care and support, and our partner Kaisheng Capital for its assistance. This financing round demonstrates the market’s strong confidence in Dessight Biomedical and further validates our leading position in the field of microsurgical robotics. We will remain dedicated to the continuous innovation of robotic microsurgical technologies, developing and providing a robotic microsurgical platform characterized by high precision, high dexterity, and high stability. This platform will enable surgeons to perform precise, quantified, and visualized operations on delicate tissues and in complex surgical procedures, thereby bringing about breakthrough technological advancements in ophthalmology and super-microsurgery.”

Zhang Shuai, Project Leader at Infinity Capital“The field of retinal diseases presents substantial unmet clinical needs, and retinal specialists urgently require supporting equipment to assist them in performing highly complex surgical procedures. Dessight Biomedical has keenly identified retinal diseases as its entry point, focusing on solutions for ultra-microsurgery. By adhering to a clinical-need-driven approach, the company has independently developed innovative technologies that effectively address the pain points faced by frontline physicians. We have observed the Dessight team, led by Dr. Cui Di, demonstrate resolute and efficient execution capabilities while maintaining their valuable entrepreneurial original aspiration, thereby creating a classic case of ‘medical-engineering integration’ in the development of innovative medical devices. Infinity Capital has long been strategically positioned in the ophthalmology sector. We are delighted to partner with Dessight Biomedical and look forward to seeing it become an indispensable and significant contributor to the fields of ophthalmology and even ultra-microsurgical treatment.”

Zhao Chunsheng, Executive Partner of Hefei Kangshi Partnership Enterprise“He stated, ‘Once Dessight Biomedical’s products under development are launched on the market, they will significantly improve the success rate of fundus and retinal surgeries, lower the technical threshold for ophthalmic surgeons, and benefit more ophthalmologists and patients. Meanwhile, as a leading enterprise in the ophthalmology industry, Autek China is comprehensively building its Optometry and Ophthalmology Medical Service Chain and ecosystem. We believe that Dessight Biomedical, Autek China, and their affiliated enterprises will have more opportunities for collaboration.’”

New Silk Road Capital“The field of surgical robotics has always been a key focus of our investment strategy. In recent years, we have strategically invested in several outstanding companies operating in different niche segments of the surgical robotics sector. As China’s population ages, there is a growing number of patients suffering from ophthalmic diseases, particularly age-related degenerative eye conditions. Against this backdrop, we are highly optimistic about the new opportunities for applying surgical robotics in ophthalmology. The advanced technologies and products developed by Dessight Biomedical have shown us the potential to provide more effective solutions for patients troubled by complex and refractory eye diseases in the future. This also adds greater possibilities for ophthalmic surgeons on the path toward precision medicine. We firmly believe that Dessight Biomedical can grow into a leading enterprise in the field of ophthalmic and microsurgical robotics, both in the domestic Chinese market and globally, ultimately benefiting more patients through clinical application.”

Fof Capital“The integration of medicine and engineering, exemplified by intelligent surgical robots, is one of the key areas Beijing Fof Capital Co., Ltd. focuses on and has strategically invested in. The microsurgical robot independently developed by Dessight Biomedical enhances precision in microsurgical procedures, transcends the physiological limitations of surgeons, effectively addresses critical clinical pain points, and holds significant potential for future applications. The founding team of Dessight Biomedical has accumulated extensive expertise in microsurgical robotics, particularly demonstrating industry-leading advantages in ophthalmic microsurgical robotic systems. Beijing Fof Capital Co., Ltd. is optimistic about Dessight Biomedical’s growth potential and will leverage its resources and experience to support the company, looking forward to a long-term partnership.”

Zou Guowen, Founding Partner of Kaicheng Capitalstated: “Kaicheng Capital is honored to serve as the exclusive financial advisor for Dessight Biomedical’s Pre-A+ financing round. With ophthalmology as its entry point, Dessight Biomedical has extended its underlying high-precision ultra-microscopic manipulation technology to applications in microsurgical procedures, surpassing the physiological limits of manual dexterity and assisting surgeons in performing ultra-complex operations. Addressing a strong clinical imperative, the company holds substantial market potential. We are fully confident that Dessight Biomedical will emerge as the leading enterprise in the fields of ophthalmic and microsurgical robotics.”

Infinity Capital Management Co., Ltd. (hereinafter referred to as “Infinity Capital”) is an equity investment platform under Huafa Group, a leading state-owned enterprise in Zhuhai and one of China’s Top 500 Enterprises. It also serves as the core entity for the Greater China operations of Infinity Group, a renowned investment management firm originating from Israel. The company primarily manages onshore RMB funds and cross-border M&A activities, with a presence in more than ten cities across China and abroad. It has established five major business regions: North China, East China, South China, Southwest China, Hong Kong, and Overseas. Infinity Capital has strategically focused on sectors including TMT (Technology, Media, and Telecommunications), Big Health and Life Sciences, Energy Conservation and Environmental Protection, Advanced Manufacturing, and New Materials. Several portfolio companies have successfully listed on the HKEX, A-share, and US stock markets, including Digital China (HK0861), Digital China Information Service (SZ000555), Will Semiconductor (SH603005), Digital Domain Holdings (SZ002280), and Baozun Inc. (BZUN). In recent years, the company has achieved sustained and stable investment performance, with multiple portfolio companies going public, such as Eternal Medical (HK01612), Asymchem (002821), Huati Technology (603679), Liancheng Precision (002921), Lihu Shares (300694), Lanjian Intelligence (688557), New Wind Power (688663), Chuangyao Technology (688259), Silinjie (688115), Haichuang Pharmaceutical (688302), and Laekna Therapeutics (HK2105). Additionally, Hongtu Separator and IOPtima were acquired by listed companies Jinguan Electric (300510) and Kanghong Pharmaceutical (002773), respectively.

New Silk Road Capital was established in 2015. With a core focus on investments in the life sciences sector, it covers multiple sub-sectors including biopharmaceuticals, medical devices, and healthcare services. The firm aims to support the development of China’s healthcare industry and address unmet patient needs through its investments in healthcare and related fields. Its core management team consists of seasoned professionals with backgrounds in medicine and pharmaceuticals, as well as extensive experience in capital markets. Having long been deeply engaged in the healthcare industry, the team has accumulated rich investment and operational expertise and achieved outstanding investment performance.

Fof Capital, established in 2012, primarily focuses on the healthcare industry and advanced manufacturing, with an emphasis on early- to mid-stage projects. Its cumulative assets under management amount to nearly RMB 7 billion. To date, it has invested in multiple companies, including Yiming Biotech, Tiluo Medical, Shiguang Technology, Saifu Pharma, Jingyi Equipment, and Jiaxuan Intelligence.

Linear Capital, established in 2014, focuses on investments at the intersection of “frontier technology and industry.” This entails applying frontier technologies—represented by data intelligence, new digital infrastructure, next-generation robotics, and technological innovations in traditional sectors (such as biomedicine, materials, and energy)—to various vertical industries. These applications significantly enhance industrial efficiency, empower industries to address critical pain points, and facilitate industrial upgrading, thereby generating excess commercial returns through substantial increases in industrial value. We adhere to an early-stage investment strategy, providing continuous support throughout the entire lifecycle of our portfolio companies. Currently, Linear Capital manages ten funds with total assets under management of approximately USD 2 billion. The firm has invested in over 120 startup teams at the early stage, including Horizon Robotics, Kujiale, Sensors Data, Tezign, Spirit AI, Thinking Analytics, Rokid, Guandata, and Topsec, with the combined valuation of its portfolio companies reaching approximately USD 20 billion.

WinX Capital is a leading investment bank in China’s healthcare sector, with headquarters in Beijing and Shanghai, covering over 3,000 active institutional investors and industrial groups. It has received numerous accolades, including being ranked No. 1 among financial advisory firms in the healthcare sector by The New Voice for “2022,” top 2 by Qimingpian & Xinsheng Chuangfu for “2021-2022 Best Financial Advisory Firms in Healthcare,” and top 5 by VCBeat for the “2022-2023 Pengcheng Award · Annual Healthcare Financial Advisor.”